|
|
|
|
| LEADER |
03016nam a2200373 u 4500 |
| 001 |
EB001839324 |
| 003 |
EBX01000000000000001003313 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 020 |
|
|
|a 0309459540
|
| 020 |
|
|
|a 9780309459549
|
| 100 |
1 |
|
|a Bonnie, Richard J.
|e [editor]
|
| 245 |
0 |
0 |
|a Pain management and the opioid epidemic
|h Elektronische Ressource
|b balancing societal and individual benefits and risks of prescription opioid use
|c Richard J. Bonnie, Morgan A. Ford, and Jonathan K. Phillips, editors ; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse, Board on Health Sciences Policy, Health and Medicine Division
|
| 260 |
|
|
|a Washington, D.C.
|b The National Academies Press
|c 2017, [2017]
|
| 300 |
|
|
|a 1 PDF file (xxv, 455 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Analgesics, Opioid / adverse effects
|
| 653 |
|
|
|a United States
|
| 653 |
|
|
|a Prescription Drug Misuse / prevention & control
|
| 653 |
|
|
|a Analgesics, Opioid / administration & dosage
|
| 653 |
|
|
|a Inappropriate Prescribing / prevention & control
|
| 653 |
|
|
|a Pain Management
|
| 653 |
|
|
|a Opioid-Related Disorders
|
| 700 |
1 |
|
|a Ford, Morgan A.
|e [editor]
|
| 700 |
1 |
|
|a Phillips, Jonathan
|e [editor]
|
| 710 |
2 |
|
|a National Academies of Sciences, Engineering, and Medicine (U.S.)
|b Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Consensus study report
|
| 500 |
|
|
|a "A consensus study of the National Academies of Sciences, Engineering, Medicine."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK458660
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring
|